Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FUFBP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Camidanlumab tesirine
|
|||||
| Synonyms |
ADCT-301; Cami; HuMax-TAC-ADC
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics SA
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 22 Indication(s)
Hodgkin lymphoma [ICD11:2B30]
Phase 2
Acute lymphoblastic leukemia [ICD11:2B33]
Phase 1
B-cell lymphoma [ICD11:2A86]
Phase 1
Bladder cancer [ICD11:2C94]
Phase 1
Burkitt lymphoma [ICD11:2A85]
Phase 1
Colorectal cancer [ICD11:2B91]
Phase 1
Cutaneous T-cell lymphoma [ICD11:2B00]
Phase 1
Diffuse large B-cell lymphoma [ICD11:2A81]
Phase 1
Esophageal cancer [ICD11:2B70]
Phase 1
Fallopian tube cancer [ICD11:2C74]
Phase 1
Follicular lymphoma [ICD11:2A80]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
Head and neck squamous carcinoma [ICD11:2C31]
Phase 1
Macroglobulinemia [ICD11:2A85]
Phase 1
Mantle cell lymphoma [ICD11:2A85]
Phase 1
Melanoma [ICD11:2C30]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Peripheral T-cell lymphoma [ICD11:2A90]
Phase 1
Renal cell carcinoma [ICD11:2C90]
Phase 1
Acute myeloid leukaemia [ICD11:2A60]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
2.25
|
|||||
| Structure |
|
|||||
| Antibody Name |
Camidanlumab
|
Antibody Info | ||||
| Antigen Name |
Interferon-stimulated gene 20 kDa protein (ISG20)
|
Antigen Info | ||||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
SG3249
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Complete Remission (CR) |
48.60% (In the cHL cohort, at 45 ug/kg)
35.00% (In the cHL cohort, at 30 ug/kg) 6.50% (in all patients with T-NHL) 10.00% (in all patients with T-NHL, 60 ug/kg doses) 7.10% (in all patients with T-NHL, 80 ug/kg doses) 0.00% (in all patients with T-NHL, 100 ug/kg doses) |
|||
| Patients Enrolled |
Relapsed or refractory classical Hodgkin lymphoma or non-Hodgkin lymphoma, an Eastern Cooperative Oncology Group performance status 0-2, who had no therapies available to them with established clinical benefit for their disease stage were enrolled.
|
||||
| Administration Dosage |
Intravenously (3-150 ug/kg) once every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02432235 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. | ||||
| Primary Endpoint |
The maximum tolerated dose was not reached. The recommended doses for expansion were 30 ug/kg and 45 ug/kg for patients with classical Hodgkin lymphoma and 80 ug/kg for patients with T-cell non-Hodgkin lymphomas. No recommended doses for expansion were defined for B-cell non-Hodgkin lymphomas.
|
||||
| Other Endpoint |
In the cHL cohort,ORR (95% CI) was 86.49% at 45 ug/kg (32/37 patients [71.20-95.50]) and 55.00% at 30 ug/kg (11/20 patients [31.50-76.90]); 48.65% (18/37 patients) and 35.00% (7/20 patients) achieved CR. Median (95% CI) DOR for the cHL population was 6.64 months (5.06-8.11),and was 7.16 months (4.57-8.51) in patients treated at 45 ug/kg.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Antecedent myelodysplastic syndrome who received treatment with hypomethylating agents and subsequently presented with CD25-positive AmL, or patients with R/R CD25-positive acute lymphocytic leukemia (ALL) who had failed or were intolerant to any established therapy, or for whom no other treatment options were available.
|
||||
| Administration Dosage |
Intravenously at 3-92 ug/kg once every three weeks (Q3W) or 30 or 37.50 ug/kg every week (QW).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02588092 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT 301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia (AML) or CD25-positive acute lymphoblastic leukemia. | ||||
| Primary Endpoint |
Two patients achieved complete responses with incomplete hematologic recovery; one each at 30.00 and 37.50 ug/kg QW.
|
||||
| Other Endpoint |
Of 16 patients with post-baseline disease assessments, two patients treated on the QW dosing regimen had a complete response (CR).
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
|
||||
| Administration Dosage |
45 ug/kg Q3W for 2 cycles and then 30 ug/kg Q3W thereafter; intravenous administration.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02432235 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. | ||||
| Primary Endpoint |
The ORR was 40%,representing 51 responders (patients achieved a best overall response of confirmed PR).
|
||||
| Other Endpoint |
Of the 130 patients included in the safety analysis, 27 (20.77%) experienced grade2 increased GGT, 17 (13.08%) experienced a grade2 neurologic AE,and 18 (13.85%) experienced a grade2 autoimmune AE at cycle 6.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 11.60% (Day 21) | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Karpas 299 with moderate CD25 expression (molecules per cell surface=76000). Compared with injection of vehicle (PBS), ADCT-301 administered intravenously (i.v.) at a mean tumor volume of 160 mm3 as a single dose at 0.1 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 41.50% (Day 32) | High CD25 expression (CD25+++; 310,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Su-DHL-1 with high CD25 expression (molecules per cell surface=310000).ADCT-301 was administered intravenously at mean tumor volume of 155 mm3 at single doses of 0.3 mg/kg and tumor growth compared with that observed after injection of vehicle (PBS).
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 51.30% (Day 21) | High CD25 expression (CD25+++; 310,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Su-DHL-1 with high CD25 expression (molecules per cell surface=310000).ADCT-301 was administered intravenously at mean tumor volume of 155 mm3 at single doses of 0.3 mg/kg and tumor growth compared with that observed after injection of vehicle (PBS).
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 68.40% (Day 21) | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Karpas 299 with moderate CD25 expression (molecules per cell surface=76000). Compared with injection of vehicle (PBS), ADCT-301 administered intravenously (i.v.) at a mean tumor volume of 160 mm3 as a single dose at 0.2 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.20% (Day 21) | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Karpas 299 with moderate CD25 expression (molecules per cell surface=76000). Compared with injection of vehicle (PBS), ADCT-301 administered intravenously (i.v.) at a mean tumor volume of 160 mm3 as a single dose at 0.4 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.10% (Day 32) | High CD25 expression (CD25+++; 310,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Su-DHL-1 with high CD25 expression (molecules per cell surface=310000).ADCT-301 was administered intravenously at mean tumor volume of 155 mm3 at single doses of 0.6 mg/kg and tumor growth compared with that observed after injection of vehicle (PBS).
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.10% (Day 21) | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Karpas 299 with moderate CD25 expression (molecules per cell surface=76000).Vechicle (PBS), ADCT-301 (dar 2.2), nonbinding ADC (DAR 2.1) or Adcetris (DAR~4) were administered intravenously at a mean Karpas 299 tumor volume of 130mm3 as single doses at 0.5 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.40% (Day 21) | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Karpas 299 with moderate CD25 expression (molecules per cell surface=76000). Compared with injection of vehicle (PBS), ADCT-301 administered intravenously (i.v.) at a mean tumor volume of 160 mm3 as a single dose at 0.6mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.80% (Day 21) | High CD25 expression (CD25+++; 310,000 CD25 molecules/cell) | ||
| Method Description |
Camidanlumab tesirine induces efficient tumor cell killing in CDX models of an anaplastic large cell lymphoma (ALCL) cell line Su-DHL-1 with high CD25 expression (molecules per cell surface=310000).ADCT-301 was administered intravenously at mean tumor volume of 155 mm3 at single doses of 0.6 mg/kg and tumor growth compared with that observed after injection of vehicle (PBS).
Click to Show/Hide
|
||||
| In Vivo Model | Anaplastic large cell lymphoma CDX model | ||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | 0.26 pM | Moderate CD25 expression (CD25++; 17,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | 4.96 pM | High CD25 expression (CD25+++; 310,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | 17.07 pM | Moderate CD25 expression (CD25++; 76,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | 19.60 pM | High CD25 expression (CD25+++; 167,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Hodgkin lymphoma | HDLM-2 cells | CVCL_0009 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | > 6667.00 pM | Negative CD25 expression (CD25-; <1,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | > 6667.00 pM | Negative CD25 expression (CD25-; <1,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | > 6667.00 pM | Negative CD25 expression (CD25-; <1,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | T lymphocytic leukemia | HuT 78 cells | CVCL_0337 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | > 6667.00 pM | Negative CD25 expression (CD25-; <1,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | KG-1 cells | CVCL_0374 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximum Growth Inhibitory Concentration (GI50) | 7.49 pM, 1.11 ng/mL | Moderate CD25 expression (CD25++; 96,000 CD25 molecules/cell) | ||
| Method Description |
The inhibitory activity of ADCT-301 against cancer cell growth was evaluated in various human cancer cell lines in vitro. CD25-positive and -negative cell lines were incubated with increasing concentrations of ADCT-301 or free warhead (SG3199) for 96 hours before processing by the MTS assay.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.